• Publications
  • Influence
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
TLDR
The results suggest that early improvements in disease-free survival noted in patients who switch to exemestane after 2-3 years on tamoxifen persist after treatment, and translate into a modest improvement in overall survival. Expand
Fertility and ageing.
TLDR
The late 20th century trend to delay birth of the first child until the age at which female fecundity or reproductive capacity is lower has increased the incidence of age-related infertility and stimulated interest in the possible factors in the female and the male that may contribute to the decline in fecundities with age. Expand
Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation.
TLDR
It is shown that combined treatment with gonadotrophins and the GnRH antagonist Cetrorelix is a promising method for ovarian stimulation in patients who frequently exhibit premature LH surges and therefore fail to complete treatment. Expand
A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists.
TLDR
Lower probability of ongoing pregnancy can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing ovarian stimulation for IVF with GnRH antagonists. Expand
GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis.
TLDR
The use of GnRH agonist to trigger final oocyte maturation in IVF, where inhibition of premature LH surge is achieved with GnRH antagonists, yields a number of oocytes capable to undergo fertilization and subsequent embryonic cleavage, which is comparable to that achieved with HCG. Expand
Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist
TLDR
The use of the LHRH antagonists might be considered more advantageous because of the short-term application needed to inhibit gonadotrophin secretion, so allowing a reduction in the treatment time in a clinically significant manner. Expand
Oral contraceptive pretreatment significantly reduces ongoing pregnancy likelihood in gonadotropin-releasing hormone antagonist cycles: an updated meta-analysis.
TLDR
Ongoing pregnancy rate (PR) per randomized woman was found to be significantly lower in patients with oral contraceptive pill pretreatment after pooling data from six randomized controlled trials encompassing 1,343 patients. Expand
Use of GnRH antagonists in ovarian stimulation for assisted reproductive technologies compared to the long protocol
TLDR
A meta-analysis of studies using cetrorelix and ganirelix against the long GnRH agonist protocol concluded that cetROrelix but not ganiresis will reduce the incidence of cases of OHSS and that cETrorelx but notGnRH antagonists will result in the same pregnancy rates as the long protocol. Expand
Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis.
TLDR
The probability of live birth after ovarian stimulation for IVF does not depend on the type of analogue used for pituitary suppression, and the result remains stable in subgroup analysis. Expand
Over‐expression of wild‐type Rad51 correlates with histological grading of invasive ductal breast cancer
TLDR
Data suggest that in addition to the absence of the tumour‐suppressor protein BRCA1, over‐expression of wild‐type Rad51 also contributes to the pathogenesis of a significant percentage of sporadic breast cancers and that other mechanisms than mutations must be responsible for this altered expression. Expand
...
1
2
3
4
5
...